246 related articles for article (PubMed ID: 29104288)
1. Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma.
Ray A; Das DS; Song Y; Hideshima T; Tai YT; Chauhan D; Anderson KC
Leukemia; 2018 Mar; 32(3):843-846. PubMed ID: 29104288
[No Abstract] [Full Text] [Related]
2. Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma.
Ray A; Song Y; Du T; Chauhan D; Anderson KC
Oncogene; 2020 Mar; 39(13):2786-2796. PubMed ID: 32024967
[TBL] [Abstract][Full Text] [Related]
3. Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA.
Bat-Erdene A; Nakamura S; Oda A; Iwasa M; Teramachi J; Ashtar M; Harada T; Miki H; Tenshin H; Hiasa M; Fujii S; Sogabe K; Oura M; Udaka K; Kagawa K; Yoshida S; Aihara KI; Kurahashi K; Endo I; Abe M
Br J Haematol; 2019 Jun; 185(5):969-974. PubMed ID: 30474853
[No Abstract] [Full Text] [Related]
4. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.
Vogl DT; Raje N; Jagannath S; Richardson P; Hari P; Orlowski R; Supko JG; Tamang D; Yang M; Jones SS; Wheeler C; Markelewicz RJ; Lonial S
Clin Cancer Res; 2017 Jul; 23(13):3307-3315. PubMed ID: 28053023
[No Abstract] [Full Text] [Related]
5. Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat.
Cavenagh JD; Popat R
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):501-507. PubMed ID: 29804873
[TBL] [Abstract][Full Text] [Related]
6. HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy.
Wen Y; Ye S; Li Z; Zhang X; Liu C; Wu Y; Zheng R; Xu C; Tian J; Shu L; Yan Q; Ai F; Ma J
Cancer Immunol Immunother; 2024 Jan; 73(1):7. PubMed ID: 38231305
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer.
Xu X; Huang Z; Zheng L; Fan Y
Int J Cancer; 2018 Jun; 142(11):2344-2354. PubMed ID: 29318609
[TBL] [Abstract][Full Text] [Related]
8. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
Hideshima T; Qi J; Paranal RM; Tang W; Greenberg E; West N; Colling ME; Estiu G; Mazitschek R; Perry JA; Ohguchi H; Cottini F; Mimura N; Görgün G; Tai YT; Richardson PG; Carrasco RD; Wiest O; Schreiber SL; Anderson KC; Bradner JE
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13162-13167. PubMed ID: 27799547
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.
Pérez-Ruiz E; Etxeberria I; Rodriguez-Ruiz ME; Melero I
Clin Cancer Res; 2017 Sep; 23(18):5326-5328. PubMed ID: 28790118
[TBL] [Abstract][Full Text] [Related]
10. Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.
Jelinek T; Paiva B; Hajek R
Front Immunol; 2018; 9():2431. PubMed ID: 30505301
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.
García-Guerrero E; Götz R; Doose S; Sauer M; Rodríguez-Gil A; Nerreter T; Kortüm KM; Pérez-Simón JA; Einsele H; Hudecek M; Danhof S
Leukemia; 2021 Jan; 35(1):201-214. PubMed ID: 32350373
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab improves survival in multiple myeloma.
Baker H
Lancet Oncol; 2016 Nov; 17(11):e480. PubMed ID: 27746105
[No Abstract] [Full Text] [Related]
13. Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?
Sponaas AM; Waage A; Vandsemb EN; Misund K; Børset M; Sundan A; Slørdahl TS; Standal T
Front Immunol; 2021; 12():636375. PubMed ID: 33679794
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.
Amengual JE; Prabhu SA; Lombardo M; Zullo K; Johannet PM; Gonzalez Y; Scotto L; Serrano XJ; Wei Y; Duong J; Nandakumar R; Cremers S; Verma A; Elemento O; O'Connor OA
Clin Cancer Res; 2017 Jun; 23(12):3084-3096. PubMed ID: 27993968
[No Abstract] [Full Text] [Related]
15. Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma.
Richardson PG; Moreau P; Laubach JP; Maglio ME; Lonial S; San-Miguel J
Pharmacol Res; 2017 Mar; 117():185-191. PubMed ID: 27884726
[TBL] [Abstract][Full Text] [Related]
16. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
17. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
Ishibashi M; Tamura H; Sunakawa M; Kondo-Onodera A; Okuyama N; Hamada Y; Moriya K; Choi I; Tamada K; Inokuchi K
Cancer Immunol Res; 2016 Sep; 4(9):779-88. PubMed ID: 27440711
[TBL] [Abstract][Full Text] [Related]
18. (N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
Lee HY; Nepali K; Huang FI; Chang CY; Lai MJ; Li YH; Huang HL; Yang CR; Liou JP
J Med Chem; 2018 Feb; 61(3):905-917. PubMed ID: 29304284
[TBL] [Abstract][Full Text] [Related]
19. Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
Wu H; Yang K; Zhang Z; Leisten ED; Li Z; Xie H; Liu J; Smith KA; Novakova Z; Barinka C; Tang W
J Med Chem; 2019 Aug; 62(15):7042-7057. PubMed ID: 31271281
[TBL] [Abstract][Full Text] [Related]
20. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Yee AJ; Bensinger WI; Supko JG; Voorhees PM; Berdeja JG; Richardson PG; Libby EN; Wallace EE; Birrer NE; Burke JN; Tamang DL; Yang M; Jones SS; Wheeler CA; Markelewicz RJ; Raje NS
Lancet Oncol; 2016 Nov; 17(11):1569-1578. PubMed ID: 27646843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
